European Commission approves Rinvoq to treat active psoriatic arthritis (PsA) and active ankylosing spondylitis.- AbbVie

AbbVie announced that the European Commission (EC) has approved Rinvoq (upadacitinib?, 15 mg), an oral, once daily selective and reversible JAK inhibitor for the treatment of adults with active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS). The EC approval is supported by data from the three pivotal clinical trials SELECT-PsA 1, SELECT-PsA 2 and SELECT-AXIS 1, demonstrating upadacitinib’s efficacy across multiple measures of disease activity. “Psoriatic arthritis and ankylosing spondylitis are multi-faceted diseases that can cause severe pain, restricted mobility, and lasting structural damage,” said Iain McInnes, Professor of Medicine and Versus Arthritis Professor of Rheumatology at University of Glasgow, UK. “In clinical trials, upadacitinib demonstrated improvements across multiple manifestations of these diseases. The approvals of upadacitinib for the treatment of PsA and AS offer physicians in the European Union an important new therapeutic option and for their patients a new opportunity to find meaningful relief from their debilitating symptoms.”